IMVTNASDAQ

Immunovant

Immunovant, Inc. · New York, NY · founded 2018

Immunovant, based in New York, develops anti-FcRn monoclonal antibodies for autoimmune diseases driven by harmful immunoglobulin G (IgG) antibodies. The drugs work by blocking FcRn — a receptor that recycles IgG in the body — which forces the immune system to break down those harmful antibodies and reduce disease activity. Lead programs batoclimab and IMVT-1402 are in trials for myasthenia gravis, thyroid eye disease, Graves' disease, and CIDP.

Lead asset: batoclimab · Ph3 · Myasthenia Gravis; mAb · anti-FcRn mAb
Pipeline: 1 drug · 1 program; 1 Immunology
Modalities: mAb×1

FocusImmunology

Last refresh · 15d ago · 8-K

$38.00+19.42%1Y

IMVT · daily close · illustrative · 1 catalyst marked

Interim+12%

1Y high$38.471Y low$31.82range$6.65(21%)past catalysts

Peers in this space

same sector or modality · sorted by match strength + market cap

1 programmatch: sector + modality

Immunologygene therapy

1 programmatch: sector

Immunologysmall molecule

1 programmatch: sector

1 programmatch: modality

Pipeline & catalysts

1 drug · 1 programs · 2 upcoming catalysts

Pipeline by phase1programs

Preclin0
Ph10
Ph20
Ph31
Filed0
Approved0

batoclimab

mAbanti-FcRn mAb

Myasthenia Gravis

Phase 3

1 program·1 trial·View drug →

Upcoming catalysts2

Conf.APR 302026·todayEXACT

Batoclimab Open-Label Extension Data — AAN 2026

Open-label extension data for batoclimab in gMG at AAN 2026. Watch: durability of MG-ADL improvement, LDL-C trajectory on chronic dosing, IgG rebound off-treatment.

Cited“Open-label extension data for batoclimab in generalized myasthenia gravis will be presented at the American Academy of Neurology Annual Meeting on April 30, 2026.”

Conference Data·8-K·disclosed 15d ago

ReadoutSEP2026·4 monthsMONTH↗ slipped

Batoclimab gMG Phase 3 Topline

Phase 3 efficacy readout for batoclimab in generalized myasthenia gravis (gMG). Approved competitor in the FcRn class: argenx VYVGART. Watch: MG-ADL change at week 12, dosing convenience (subq vs. IV), LDL elevation profile.

Cited“Topline data from the Phase 3 study of batoclimab in generalized myasthenia gravis is now expected in September 2026.”

Topline Readout·8-K·disclosed 15d ago·NCT05425927n=240·was Q3 '26

Past catalyst impact

4 historical events · % change vs announcement

DateKindEventOutcome+1W+1M+6M

Jul 29, 2025Interimbatoclimab — Phase 3 Interim — Stopped for EfficacyMixed+11.9%-20.1%+11.6%

Mar 1, 2025PDUFAbatoclimab — PDUFA — ApprovedPositive+37.0%+43.4%+20.7%

Jul 4, 2024AdCombatoclimab — Advisory Committee — 12–2 Vote in FavorPositive+30.0%+34.6%+15.9%

Sep 8, 2023Interimbatoclimab — Phase 3 Interim — Stopped for EfficacyPositive+18.8%+9.6%+17.7%

% change vs ticker close on the announcement date · backtest illustrative

Smart money

Insider activity

SEC EDGAR Form 4 · last 90 days

Insider activity · last 90 days

Form 4 trail · 3 transactions · 3 insiders

3 near a catalyst

Net flow

+$0

Buys

0 txns

Sells

0 txns

Largest

—

Net flow per quarter · last 8Q

6 txns · sum +$253K

24Q324Q425Q125Q225Q325Q426Q126Q2

buys · $253Ksells · $0

Insider · roleActionSharesPriceValueDate

S. Mendoza

Chair

Option ex.7,417$37.23$276.1K

Apr 17, 2026

E. Andersson

CMO

Option ex.2,575$46.37$119.4K

Apr 14, 2026

M. Chen

CMO

Option ex.12,616$48.16$607.6K

Apr 7, 2026

Congressional trading

STOCK Act PTRs · House & Senate

Congressional trading · STOCK Act · last 365d

2 trades · 2 members

Est. net flow

−$925K

midpoint · brackets only

Buys

Sells

Party mix

1 D1 R

Member · chamberActionBracket~ midpointOwnerDate · disclosure

Rep. Q. Yates

House · AL

Sell$100K–$250K~$175Kself

Jan 13, 2026

filed +44d

Sen. E. Mendoza

Senate · AZ

Sell$500K–$1.00M~$750Kspouse

Nov 12, 2025

filed +32d

Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value

Top ETF holders

ETF NAV disclosures · 13F filings

ETF holders · NAV disclosures

3 ETFs hold the position

Held by ETFs

$18.4M

aggregate position

Of market cap

0.32%

aggregate ETF share

Top holder

XBI0.18%

SPDR S&P Biotech ETF

TickerETF · familyThemeNAV% of NAVPosition

XBI

SPDR S&P Biotech ETF

SPDR

Broad biotech$7.90B0.18%$14.2M

SBIO

ALPS Medical Breakthroughs ETF

First Trust

Small-cap biotech$110.0M3.66%$4.0M

PBE

Invesco Dynamic Biotechnology

Invesco

Broad biotech$175.0M0.10%$175K

Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund

KOL network

CMS OpenPayments · 2024 – 2025

KOL network · CMS OpenPayments

12 physicians paid · 54 disclosed records

Total 2025+2024

$3.62M

YoY

+15%

Research Grant$1.36MEquity / Ownership$1.21MCo-Investigator$812.4KSpeaking$122.8KConsulting$92.8KTravel & Lodging$18.4KFood & Beverage$1.8K

Physician · affiliationSpecialtyTop categoryTotalRecords

Dr. Tomás Park

Yale Medical

Allergy & ImmunologyCo-Investigator$703.6K6

Dr. Kavya Goldstein

Memorial Sloan Kettering

RheumatologyCo-Investigator$637.9K5

Dr. Vivian Tanaka

University of Washington

Allergy & ImmunologyResearch Grant$489.7K5

Dr. Theo Müller

MD Anderson

RheumatologyEquity / Ownership$460.7K6

Dr. Ahmed Müller

Memorial Sloan Kettering

RheumatologyResearch Grant$385.3K7

Dr. Liam O'Connor

University of Michigan

DermatologyEquity / Ownership$218.2K4

Dr. Olivia Goldstein

Vanderbilt

DermatologyResearch Grant$196.8K2

Dr. Yuki Mendoza

Duke University

Allergy & ImmunologyEquity / Ownership$173.7K7

Dr. Henry Park

NYU Langone

RheumatologyEquity / Ownership$156.1K6

Dr. Henry Andersson

NYU Langone

RheumatologyResearch Grant$113.8K2

Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs

Government & IP

Federal lobbying

Senate LDA disclosures · last 8 quarters

Federal lobbying · LDA · last 8 quarters

$748K disclosed · 2 firms engaged

YoY change

+22%

last 4Q vs prior 4Q

24Q3Q425Q1Q2Q3Q426Q1Q2

Top lobbying firms · last 8Q

K&L Gates$381K

5 quarters active

Van Scoyoc Associates$367K

5 quarters active

Top issues lobbied

Inflation Reduction Act drug pricing carve-outs$381K
Inflation Reduction Act drug-price negotiation$367K

Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed

Government contracts

USAspending.gov · BARDA · NIH · DoD · HHS · VA

Federal contracts · USAspending.gov

1 award · 1 agency

Total awarded

$43.8M

across all programs

Active

$43.8M

option periods incl.

Top agency

NIH / NCI$43.8M

largest active: Immuno-Oncology Combination Trial Sponsorship

AgencyTitle · type · award IDStatusValueAwarded → ends

NIH / NCI

Immuno-Oncology Combination Trial Sponsorship

Cooperative Agreement · NIH-08375102

active$43.8MSep 2025→ Feb 2028

Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)

U.S. Patents

USPTO PEDS & Patent Public Search

U.S. Patents · USPTO

6 granted · 1 pending

Total in portfolio

Granted in last 12mo

Expiring < 2yr

Nearest expiry

Apr 2029

Patent #Title · inventor · drugTypeStatus · filedExpiry

12,027,663

Modified RNA constructs and methods of use thereof batoclimab

K. Iyer + 3 · batoclimab

Composition of Matter

grantedfiled Apr 2024

exp. Apr 2044

18.0y left

10,362,370

Combination therapy comprising batoclimab

R. Chen + 1 · batoclimab

Method of Use

grantedfiled Apr 2018

exp. Apr 2038

12.0y left

US 2019/2073310 A1

Sustained-release oral compositions of batoclimab

J. Chen · batoclimab

Formulation

pendingfiled Apr 2019

in prosecution

11,481,126

Dosing regimens for chronic administration of batoclimab

T. Hoffman + 3 · batoclimab

Method of Use

grantedfiled Apr 2016

exp. Apr 2036

10.0y left

12,124,691

Modified RNA constructs and methods of use thereof batoclimab

N. Romano + 3 · batoclimab

Composition of Matter

grantedfiled Apr 2010

exp. Apr 2030

4.0y left

12,054,644

Gene therapy delivery system for batoclimab

R. Reyes + 1 · batoclimab

Device

grantedfiled Apr 2011

exp. Apr 2031

5.0y left

11,947,728

Pre-filled syringe formulations comprising batoclimab

T. Park + 1 · batoclimab

Formulation

grantedfiled Apr 2009

exp. Apr 2029

3.0y left

Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing

News

PR wires · biotech trades · company IR · last 90 days

News · last 90 days

5 items from 4 categories

earnings2analyst1regulatory1clinical1

5d ago

Analyst initiates coverage of IMVT with Buy rating

STAT$·analyst

16d ago

FDA grants Breakthrough Therapy Designation to IMVT's batoclimab

FierceBiotech·regulatory

23d ago

IMVT to host Q1 earnings call and pipeline review

Business Wire·earnings

1mo ago

IMVT reports Q4 results, reaffirms 2026 guidance

Business Wire·earnings

3mo ago

IMVT presents batoclimab data at major medical conference

Endpoints News$·clinical

Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline

Financials

snapshot · sourced to filings · refreshed at next 10-Q

Trading

Previous close

$38.00

Open

$37.92

Day Δ

+0.08

+0.21%

Day range

$37.67 – $38.25

52W range

$31.82 – $38.47

Avg daily volume

1.95M

Valuation & ownership

Enterprise value

$5.3B

Shares out

150.00M

Float

130.50M

Insider %

14.90%

Institutional %

54.90%

Beta

2.40

vs SPY · 52w

Balance sheet & burn

Cash + invest

$840M

Total debt

$371M

Debt / equity

2.90

Cash burn / Q

$81M

R&D spend TTM

$284M

34% of cash

ATM available

$855M

dilution risk

Earnings

EPS latest

$-0.55

EPS Δ vs prior

+0.10

EPS estimate

$-0.45

next quarter

EPS prior

$-0.65

Next earnings

Jul 7, 2026

Rev guidance

$143M

All values reflect the most recent 10-Q / 10-K filing or seeded equivalent. Beta, IV, short interest, and borrow availability are derived from broker-feed conventions. Upgrade to Pro for live updates.

Recent disclosure activity

last 3 observations

15d agobatoclimabBatoclimab gMG Phase 3 ToplineHigh8-K

15d agobatoclimabBatoclimab Open-Label Extension Data — AAN 2026High8-K

1mo agobatoclimabBatoclimab gMG Phase 3 ToplineHigh8-K